Last reviewed · How we verify
Paratyphoid fever — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Unasyn | AMPICILLIN | Bristol-Myers Squibb | Penicillin-class Antibacterial | Transient receptor potential cation channel subfamily M member 4 | 1965-01-01 | |
| Chlorocidin | CHLORAMPHENICOL | Parkedale | Amphenicol-class Antibacterial | Cytochrome P450 3A4 | 1950-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Bristol-Myers Squibb · 1 drug in Paratyphoid fever
- Parkedale · 1 drug in Paratyphoid fever
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Paratyphoid fever:
- Paratyphoid fever treatment updates — RSS
- Paratyphoid fever treatment updates — Atom
- Paratyphoid fever treatment updates — JSON
Cite this brief
Drug Landscape (2026). Paratyphoid fever — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/paratyphoid-fever. Accessed 2026-06-10.
Related
- Paratyphoid fever full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing